

History of nephrotic syndrome and evolution of its treatment

[Health & Medicine](#)



**ASSIGN
BUSTER**

History of Nephrotic Syndrome

Nephrotic syndrome, as we know it today, is a combination of proteinuria, hypoalbuminemia, hyperlipidemia, and edema, a concept that took some time to be developed. Interestingly, the effective treatments became available only recently in the mid 1900s, with the advent of steroids, antibiotics, diuretics, and other immunomodulators. Even today, there is a gap in our understanding of the etiology(s) of nephrotic syndrome of childhood, and better treatments are still required in the more resistant forms. Nephrotic syndrome as such is a combination of clinical and laboratories findings that is seen with a variety of pathologic lesions affecting the glomerulus.

Generalized edema, referred to as dropsy in the earlier literature, has been documented from the times of Hippocrates ([1](#), [2](#)), although the differentiation between various causes (heart vs. liver vs. nutritional disturbances vs. renal abnormalities) was not made. One observation by Hippocrates was: “ when bubbles settle on the surface of the urine, it indicates a disease of the kidney and that the disease will be protracted” ([1](#)). Cornelus Roelans of Belgium described in 1484 a child with nephrotic syndrome and “ whole body swelling.” He went on to recommend the treatment as follows: “ take the tops of elder plant and daneswort, cook in white wine and wrap the child in hot clothes by applying the poultice in whole or in part, and so cure him” ([3](#)).

During the sixteenth to eighteenth centuries, dropsy was considered a disease *per se* , the patient had dropsy, without differentiating between the

causes ([4](#)). One of the first accurate descriptions of nephrotic syndrome in children was made by Theodore Zwinger of Basel in 1722 ([5](#)). He also noted decreased urine output and attributed this to “ obstruction and compression of the tubules of the kidney,” thus placing the seat of the disease in the kidney, since at that time, it was recognized that in pediatric practice heart and liver disease rarely manifest. His important observation had little influence on the scientific community, and his findings were not quoted by any author in the following 200 years. Of note, these observations were made even before Morgagni was able to establish the idea that disease might arise from specific organs ([6](#)). Morgagni’s disciple William Heberden went on to say: “ Dropsy is very rarely an original distemper but generally a symptom of some other which is too often incurable” ([7](#)).

Later in the eighteenth century, dropsy was divided into those dependent on morbid viscera (liver and heart) and a general form, supposedly inflammatory. With humoralism, a prevalent concept in Europe at that time, bloodletting was a common practice for these so called “ inflammatory diseases” and was commonly prescribed. Around the same time, several observers [namely, Cotugno ([8](#)), Cruikshank ([9](#)), Wells ([10](#)), and Brande ([9](#))] noted coagulability of urine in the patients. It was finally in 1827 that Richard Bright (1789–1858) was able to put together the triad of generalized edema, proteinuria, and kidney disease, as presenting features of this disease ([11](#)). John Bostock, a colleague of Bright, also noted that when protein in the urine was highest, it was lowest in the serum ([11](#)). Christison confirmed these findings in 1829 ([12](#)). Hence by 1830, nephrotic syndrome of profound albuminuria, hypoalbuminemia, and edema, resulting from

diseased kidneys was established. Subsequently, on the postmortem analysis, these kidneys revealed a diseased state. Bright described three varieties of postmortem appearance of the kidneys, Christison seven, Pierre Rayer six in 1840, and Carl Rokitansky no less than eight in 1846, including the “specknierre” or bacon kidney, recognized later as amyloidosis ([9](#)).

Over the next few years, the various lipid abnormalities in nephrotic syndrome became the forefront of discussion. Lutescent or milky appearance of the serum was known to be present in nephrotic syndrome (noted with bloodletting sessions). Christison showed this to be from ether soluble fat ([13](#)). In 1846, Johnson not only described the fatty nature of the kidneys on gross appearance in many such patients but also fat globules and fat casts in the tubules ([14](#)). More attention was given to the cellular and tubular components of the kidneys as they were more obvious by the histological techniques available at that time.

Virchow introduced the term “parenchymatous nephritis” for a pathological picture with primary tubular involvement ([15](#)). With advances in microscopy, glomerular involvement became clearer along with that of the parenchyma. In acute nephritis, the presence of pale exsanguinated glomeruli was long known. In 1872, Klebs coined the term “glomerulonephritis” to describe the exudative glomerular changes seen under the microscope ([16](#)). In 1905, the term “nephrosis” was coined by Müller to describe all “non-inflammatory” diseases of the kidney as a substitute for parenchymatous nephritis, contrasting it with exudative and inflammatory disease, which would retain the name nephritis ([17](#)). This

concept of “nephritis in contrast to nephrosis” was further popularized by F. Volhard, T. Fahr, and C. Munk.

Treatments for Nephrotic Syndrome

Introduction of the renal biopsy in the mainstream clinical practice of nephrology during the 1950s–1960s added a new dimension to the understanding of the histological findings in nephrotic syndrome. The histological classifications were based on the light microscopic appearance and included membranous glomerulonephritis, proliferative glomerulonephritis, a mixed membranous and proliferative glomerulonephritis, diabetic nephropathy with hyaline nodules, and focal segmental glomerular sclerosis; these are summarized in a case series from 1958 ([18](#)). The availability of electron microscopy and immunofluorescent localization of proteins was a welcomed coincidence. These new techniques transformed the ideas on morphology and pathogenesis, and made definite correlations between clinical presentation and pathological picture. The 1961, a Ciba Foundation symposium on the use of the renal biopsy was a landmark in these regards ([19](#)).

Antibiotics played an important role in treating the infections that arose from nephrotic syndrome, and the mortality rate reduced drastically from two-third to 35% ([20](#)). It is important to point out that prior to availability of steroids multiple desperate treatments were tried. A study from Boston noted the various treatments that were attempted from 1926 to 1948 for nephrotic syndrome. Dietary modification and low salt diet were probably the most effective treatments at that time. There were some weak mercurial

diuretics with little if any action. Other drastic measures, such as the induction of measles and vaccinia, were instituted. Many of the children inoculated had some form of post-infection diuresis and decrease in proteinuria (11 out of 14), only to recur. Other supportive measure included blood transfusions, antibiotic therapy, treatment with thyroid extract, decapsulation of the kidney, testosterone, multiple vitamins, horse antiserum, and parathyroid hormone.

Steroid hormones were first isolated and identified in 1936 ([21](#), [22](#)). By 1946, cortisone was first prepared by partial synthesis from bile acids ([23](#)). On the other hand, adrenocorticotrophic hormone (ACTH) was extracted from pig and sheep pituitary gland by isoelectric precipitation ([22](#), [24](#)) in the 1940s. One preparation of ACTH was commercially available as sterile powder reconstituted with isotonic saline for intramuscular injection. In the early 1950s, intramuscular injections of Cortisone ([25](#)) and ACTH ([26](#)) were first being used for treatment for nephrotic syndrome in children by Arneil and Wilson from Glasgow. These were relatively short courses, 5 days of daily 100–300 mg of intramuscular cortisone in the first study and 40–80 mg of an ACTH intramuscular injection for 12 days in the second study ([25](#), [26](#)). Later on, prednisone was first synthesized by oxidation of cortisone ([27](#), [28](#)). ACTH and cortisone were quickly replaced by prednisolone and prednisone as they could be administered orally without the need for daily injections ([29](#), [30](#)). With the advent of steroid therapy, mortality from nephrotic syndrome dramatically decreased to 3% ([31](#)).

An important series of studies, in the era after renal biopsy and steroids, to better understand the management of childhood nephrotic syndrome were heralded by the International Study of Kidney Disease in Children (ISKDC) established in 1965 with participants from North America, Europe, and Asia. A series of prospective, multicenter cooperative studies by the ISKDC established definitions, clinicopathological correlations, and recommendations for therapy that provided a basis for diagnosis and management of pediatric nephrotic syndrome that persists today. Between January 1967 and June 1974, children with the nephrotic syndrome who were older than 12 weeks and younger than 16 years were enrolled into the clinical survey from the 24 participating clinics ([32](#) - [34](#)). Of the 521 entered, 76.6% had minimal-change nephrotic syndrome, 7.5% had membranoproliferative glomerulonephritis, and 6.9% had focal segmental glomerulosclerosis ([35](#)). All participants had biopsies prior to starting steroid therapy with prednisone. Initial treatment was 60 mg/24 h/m² (maximum dosage 80 mg/24 h) in divided doses for 4 weeks, followed by 40 mg/24 h/m² in divided doses, three consecutive days out of seven for 4 weeks. A seminal observation was made that patients with non-minimal lesions had a varied and limited response to steroids ([36](#)).

Azathioprine, a purine synthesis inhibitor, was also tested by this group in a randomized placebo-controlled trial ([37](#)). Patients that were considered to be early non-responders to steroids (not responding to the initial 8-week therapy) or frequently relapsing were randomized to receive every other day prednisone with azathioprine (test group) or placebo (control group). No

significant decrease in proteinuria or number of relapses was noted in the test group vs. the control group ([37](#)).

The use of an alkylating agent in steroid-resistant nephrotic syndrome was first initiated with nitrogen mustard as early as 1958 ([38](#)). This was extended to other alkylating agents, cyclophosphamide and chlorambucil, in the 1960s and prompted the ISKDC to conduct a randomized control trial to define the role of cyclophosphamide in children with early non-responders and frequently relapsing nephrotic syndrome. Cyclophosphamide was shown to remit proteinuria in early non-responders and decrease the number of relapses of nephrotic syndrome ([39](#)). Thus, it proved to be an important agent to decrease steroid use and prevent steroid toxicity, although it caused gonadal failure in post-pubertal males ([39](#)). Chlorambucil, although noted to be as effective as cyclophosphamide ([40](#)), had concerning side effects of acute leukemia and renal carcinoma ([41](#)).

The initial 8-week steroid regimens (4 weeks daily and 4 weeks every other day) were then compared with a longer steroid treatment duration in the late 1980s ([42](#)). Mounting evidence supported a longer duration of steroids, which helped decrease the number of future relapses and steroid dependence, and the initial 8-week steroid regimen has been recommended to be increased to at least 12 weeks ([43](#) , [44](#)).

Levamisole, known for its anthelmintic, was first reported to be used in children with nephrotic syndrome in 1980 ([45](#)) and continues to be used as a steroid sparing agent in many countries. Cyclosporine A (CsA), a calcineurin inhibitor, was first isolated from the fungus *Tolypocladium*

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

inflatum found in a soil sample obtained in 1969 from Norway, by Hans Peter Frey ([46](#)). It was initially used in humans for renal transplantation in 1978 and has since changed the face of transplantation ([47](#)). The first use for CsA was reported in 1986 among adults with difficult to treat nephrotic syndrome ([48](#)). By the late 1980s, there were reports of its successful use in children with steroid-resistant or steroid-dependent nephrotic syndrome that had not responded well to alkylating agents with the target levels of CsA between 50 and 200 ng/ml ([49](#) , [50](#)).

Tacrolimus, another calcineurin inhibitor, was first extracted from *Streptomyces tsukubaensis* in 1987 by a Japanese group ([51](#)) and was initially used as a drug in human organ transplantation. Its use for nephrotic syndrome was first started in adults in the early 1990s ([52](#) - [54](#)) and then reported to be used children by the early 2000s ([55](#) - [57](#)). It was shown to be similar to CsA with regard to efficacy and renal toxicity but without the cosmetic side effects of hirsutism and gingival hypertrophy ([58](#)).

Mycophenolate mofetil (cellcept[®]) and, more recently, mycophenolate sodium (myfortic[®]) are prodrug forms of mycophenolic acid, another purine synthesis inhibitor, identified from *Penicillium* species. It was first reported to be used in pediatric nephrotic syndrome in 2000 ([59](#)) after being successfully applied in other glomerular diseases ([60](#)) and renal transplantation. It has been shown to be useful in steroid-dependent and frequently relapsing steroid-sensitive nephrotic syndrome, as a first-line agent, although there is evidence to indicate that it is probably less effective than calcineurin inhibitors ([43](#) , [61](#) - [63](#)).

Rituximab, a monoclonal antibody against a B-lymphocyte antigen CD20, came into the armamentarium after case reports describing the incidental finding of a beneficial effect of rituximab on childhood nephrotic syndrome ([64](#)). Benz et al. first used rituximab to treat ITP, resistant to steroids and immunoglobulin therapy, in a 16-year-old boy who also suffered from steroid-dependent nephrotic syndrome. As well as effectively resolving the ITP, rituximab also improved the nephrotic syndrome, inducing a relapse-free period for over 12 months on low-dose CsA ([65](#)). In the other two cases, rituximab was used to treat post-transplant lymphoproliferative disease (PTLD) in boys who also had recurrence of FSGS in their transplants ([66](#), [67](#)), with beneficial effects on proteinuria. Its efficacy was recently demonstrated as a steroid-sparing agent in childhood onset frequently relapsing and steroid-dependent nephrotic syndrome by a multicenter, double-blind, randomized, and placebo-controlled trial ([68](#)) conducted by Iijima et al. Patients in the rituximab-treated group were relapse-free for prolonged period of time despite being weaned off other immunosuppressants such as mycophenolate or cyclosporine. There have been few case reports of its efficacy in refractory primary FSGS; however, controlled clinical trials are needed to define its exact role ([69](#), [70](#)). It has been proven to be effective in combination with plasmapheresis for post-transplant recurrence of FSGS ([70](#), [71](#)). Part of this effect may be mediated by its direct action on the podocyte ([72](#)).

Future Treatments and Conclusion

Interestingly, ACTH is currently reemerging as a potential treatment for nephrotic syndrome. In Europe, it is available as a synthetic depot

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

formulation (Synacthen[®]) and in the US as a highly purified formulation (Acthar[®] gel) from porcine or bovine sources ([73](#)). There are reports on its efficacy in multiple causes of nephrotic syndrome, including idiopathic membranous nephropathy, FSGS, minimal-change disease, and mesangial glomerulonephritis, with a response rate varying from 29 to 100% ([73](#) – [79](#)). Recently, it has been shown to be particularly beneficial in idiopathic membranous nephropathy. Although the exact mechanism of action for ACTH is not known, it is thought to act directly on the podocytes *via* melanocortin receptors on the podocytes. There is need for a multicenter randomized control trial to assess its use in idiopathic nephrotic syndrome.

With discovery of various gene defects associated with nephrotic syndrome, there is an expanding knowledge of various podocyte signaling pathways that play a role in the pathogenesis of nephrotic syndrome ([80](#)). A better understanding of these pathways is needed to develop future targeted therapy. The high risk variant genotype of APOL1 gene (codes of apolipoprotein 1, known for its trypanolytic properties), was found to confer increased risk to kidney disease by gene-wide association studies (GWAS) ([81](#) – [83](#)). However, its association and role in nephrotic syndrome and podocyte biology are yet to be defined ([80](#)). New drugs on the horizon, such as losmapimod (p38 MAPK inhibitor), sparsentan (endothelin receptor type 1A antagonist), and biologics, such as adalimumab (anti-TNF- α) and abatacept (anti-CD80), hold promise in the treatment of steroid-resistant nephrotic syndrome and prevention of renal progression ([79](#)).

In summary, the seminal contributions of the ISKDC identified the importance of global collaborations in order to conduct meaningful multicenter trials aimed at effectively treating children with nephrotic syndrome, preventing renal progression and facilitating the opportunity for each child to reach their full potential and quality of life. The availability of advanced genetic and molecular applications to personalized medicine offer unique opportunities along this promising journey.

Author Contributions

The authors contributed to the manuscript. Dr. AP is the first author as he did most of the work in reviewing the literature and formatting the style and content of the submission. Dr. AP is the corresponding author.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Chadwick J. *The Medical Works of Hippocrates: A New Translation from the Original Greek* (Vol. 174). Oxford: Blackwell (1950) (Section 7, No 34).

[Google Scholar](#)

2. Cameron JS. Five hundred years of the nephrotic syndrome: 1484-1984. *Ulster Med J* (1985) 54: S5-19.

[PubMed Abstract](#) | [Google Scholar](#)

3. Roelans C. *Liber de Aegritudinibus Infantium* . München: Verl. der Muñchner Dr. (1484).

[Google Scholar](#)

4. Cameron JS, Hicks J. The origins and development of the concept of a “nephrotic syndrome”. *Am J Nephrol* (2002) 22(2-3): 240-7. doi: 10.1159/000063768

[CrossRef Full Text](#) | [Google Scholar](#)

5. Zwinger T. Anasarca puerorum. In: Basel E, Thurnis JR, editors. *Paedioatreaia Pract Curationem Puerorumque Morborum Puerilium etc* . Vol. 5 (1974). p. 659-66.

[Google Scholar](#)

6. Morgagni G. *De Sedibus et Causis Morborum. Epist XVIII* . Venice: Remondini (1760).

[Google Scholar](#)

7. Heberden W. *Commentaries on the History and Cure of Diseases* . (1802). Available from: <https://books.google.com/books?hl=en&lr=&id=DS5AAQAAMAAJ&pgis=1>

[Google Scholar](#)

8. Cotugno D. *De ischiade nervosa commentarius* . (1770). Available from: <https://archive.org/details/dominicicotunnii00cotu>

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

[Google Scholar](#)

9. Cameron JS. The nephrotic syndrome: A historical review. In: Cameron JS, Glassock RJ, editors. *The Nephrotic Syndrome*. New York: Dekker (1988). p. 3–56.

[Google Scholar](#)

10. Wells WC XVII. On the presence of the red matter and serum of blood in the urine of dropsy, which has not originated from scarlet fever. *Tr Soc Improv Med Clin Knowl* (1812) 3: 194–240.

[Google Scholar](#)

11. Bright R. *Reports of Medical Cases*. London: Orme (1827).

[Google Scholar](#)

12. Christison R. Observations on the variety of dropsy which depends on diseased kidney. *Edin Med Surg J* (1929) 32: 262–91.

[Google Scholar](#)

13. Christison R. On the cause of the milky and whey-like appearances sometimes observed in the blood. *Edin Med Surg J* (1830) 33: 274–80.

[Google Scholar](#)

14. Johnson G. On the minute anatomy and pathology of Bright's disease of the kidney, and on the relation to the renal disease to those diseases of the

liver, heart and arteries with which it is associated. *Med Chir Trans* (1846) 29: 1–43. doi: 10. 1177/095952874602900102

[CrossRef Full Text](#) | [Google Scholar](#)

15. Virchow R. *Cellular Pathology as Based upon Physiological and Pathological Histology* . Philadelphia: J. B. Lippincott (1863).

[Google Scholar](#)

16. Klebs T. *Handbuch Der Pathologischen Anatomie* . Berlin: Hirschwald (1870). p. 634.

[Google Scholar](#)

17. Müller F. Morbus Brightii. *Verh Dtsch Ges Path* (1905) 9: 64–99.

[Google Scholar](#)

18. Kark RM, Pirani CL, Pollak VE, Muehrcke RC, Blainey JD. The nephrotic syndrome in adults: a common disorder with many causes. *Ann Intern Med* (1958) 49(4): 751–4. doi: 10. 7326/0003-4819-49-4-751

[CrossRef Full Text](#) | [Google Scholar](#)

19. Cameron JS, Hicks J. The introduction of renal biopsy into nephrology from 1901 to 1961: a paradigm of the forming of nephrology by technology. *Am J Nephrol* (1997) 17(3–4): 347–58. doi: 10. 1017/CBO9781107415324.004

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

20. Arneil GC. The nephrotic syndrome. *Pediatr Clin North Am* (1971) 18(2): 547-59.

[Google Scholar](#)

21. Mason HL, Myers CS, Kendall EC. The chemistry of crystalline substances isolated from the suprarenal gland. *J Biol Chem* (1936) 114(3): 613-31.

[Google Scholar](#)

22. Thorn GW, Forsham PH, Frawley TF, Hill SR, Jr., Roche M, Staehelin D, et al. The clinical usefulness of ACTH and cortisone. *N Engl J Med* (1950) 242(22): 865-72. doi: 10. 1056/NEJM195006012422205

[CrossRef Full Text](#) | [Google Scholar](#)

23. Sarett LH. Partial synthesis of pregnene-4-triol-17(beta), 20(beta), 21-dione-3, 11 and pregnene-4-diol-17(beta), 21-trione-3, 11, 20 monoacetate. *J Biol Chem* (1946) 162: 601-31.

[Google Scholar](#)

24. Sayers G, White A, Long CNH. Preparation and properties of pituitary adrenotropic hormone. *J Biol Chem* (1943) 149(2): 425-36.

[Google Scholar](#)

25. Arneil GC, Wilson HEC. Cortisone treatment of nephrosis. *Arch Dis Child* (1952) 27(134): 322-8. doi: 10. 1136/adc. 27. 134. 322

[CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

26. Arneil GC, Wilson HE. A. C. T. H. in nephrosis. *Arch Dis Child* (1953) 28(141): 372–80. doi: 10. 1136/adc. 28. 141. 372

[CrossRef Full Text](#) | [Google Scholar](#)

27. Nobile A. The discovery of the δ 1, 4-steroids, prednisone, and prednisolone at the Schering Corporation (USA). *Steroids* (1994) 59(3): 227–8. doi: 10. 1016/0039-128X(94)90033-7

[CrossRef Full Text](#) | [Google Scholar](#)

28. Herzog H, Oliveto EP. A history of significant steroid discoveries and developments originating at the Schering Corporation (USA) since 1948. *Steroids* (1992) 57(12): 617–23. doi: 10. 1016/0039-128X(92)90014-Z

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

29. Chaudhuri JN, Ghosal SP. Observations on prednisolone treated cases of nephrotic syndrome. *Indian J Pediatr* (1958) 25(5): 201–9. doi: 10. 1007/BF02903017

[CrossRef Full Text](#) | [Google Scholar](#)

30. Barbieri DD. [Early results of prednisone therapy of nephrotic syndromes]. *Minerva Med* (1955) 46(99): 1728.

[Google Scholar](#)

31. Report of the International Study of Kidney Disease in Children, Barnett HL, Edelmann CM. Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation. *Pediatrics* (1984) 73(4): 497-501.

[Google Scholar](#)

32. A Report of the International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. *Kidney Int* (1978) 13(2): 159-65.

[Google Scholar](#)

33. A report of the International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. *J Pediatr* (1981) 98(4): 561-4. doi: 10.1016/s0022-3476(81)80760-3

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

34. Barnett HL. International study of kidney disease in children. *Jpn J Nephrol* (1979) 21(10): 1141-4. doi: 10.14842/jpnjnephrol1959.21.10_1141

[CrossRef Full Text](#) | [Google Scholar](#)

35. Report. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. *Kidney Int* (1981) 20(6): 765-71. doi: 10.1038/ki.1981.209

[CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

36. Churg J, Habib R, White RR. Pathology of the nephrotic syndrome in children. *Lancet* (1970) 295(7660): 1299–302. doi: 10. 1016/S0140-6736(70)91905-7

[CrossRef Full Text](#) | [Google Scholar](#)

37. Abramowicz M, Barnett HL, Edelmann CM, Greifer I, Kobayashi O, Arneil GC, et al. Controlled trial of azathioprine in children with nephrotic syndrome. *Lancet* (1970) 295(7654): 959–61. doi: 10. 1016/S0140-6736(70)91093-7

[CrossRef Full Text](#) | [Google Scholar](#)

38. West CD. Use of combined hormone and mechlorethamine (nitrogen mustard) therapy in lipoid nephrosis. *AMA J Dis Child* (1958) 95(5): 498–515.

[Google Scholar](#)

39. Mcdonald J, Arneil GCC, Murphy AV, Arneil GCC. Long-term assessment of cyclophosphamide therapy for nephrosis in children. *Lancet* (1974) 304(7887): 980–2. doi: 10. 1016/S0140-6736(74)92073-X

[CrossRef Full Text](#) | [Google Scholar](#)

40. Schoeneman MJ, Spitzer A, Greifer I. Nitrogen mustard therapy in children with frequent-relapsing nephrotic syndrome and steroid toxicity. *Am J Kidney Dis* (1983) 2(5): 526–9. doi: 10. 1016/S0272-6386(83)80094-8

[CrossRef Full Text](#) | [Google Scholar](#)

41. Grupe WE, Makker SP, Ingelfinger JR. Chlorambucil treatment of frequently relapsing nephrotic syndrome. *N Engl J Med* (1976) 295(14): 746-9. doi: 10. 1056/NEJM197609302951402

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

42. Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Nonoda T, Matsumoto J, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. *J Pediatr* (1988) 112(1): 122-6. doi: 10. 1016/S0022-3476(88)80136-7

[CrossRef Full Text](#) | [Google Scholar](#)

43. Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. *Pediatr Nephrol* (2013) 28(3): 415-26. doi: 10. 1007/s00467-012-2310-x

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

44. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. *Cochrane Database Syst Rev* (2015) 3: CD001533. doi: 10. 1002/14651858. CD001533. pub5

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

45. Tanphaichitr P, Tanphaichitr D, Sureeratanan J, Chatasingh S. Treatment of nephrotic syndrome with levamisole. *J Pediatr* (1980) 96(3 Pt 1): 490-3. doi: 10. 1016/S0022-3476(80)80707-4

[CrossRef Full Text](#) | [Google Scholar](#)

46. Svarstad H, Bugge HC, Dhillion SS. From Norway to Novartis: cyclosporin from *Tolypocladium inflatum* in an open access bioprospecting regime. *Biodivers Conserv* (2000) 9(11): 1521–41. doi: 10. 1023/A: 1008990919682

[CrossRef Full Text](#) | [Google Scholar](#)

47. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. *Lancet* (1978) 2(8104–5): 1323–7.

[PubMed Abstract](#) | [Google Scholar](#)

48. Meyrier A, Simon P, Perret G, Condamin-Meyrier MC. Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A. *Br Med J (Clin Res Ed)* (1986) 292(6523): 789–92. doi: 10. 1136/bmj. 292. 6523. 789

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

49. Niaudet P, Habib R, Tete MJ, Hinglais N, Broyer M. Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. *Pediatr Nephrol* (1987) 1(4): 566–73. doi: 10. 1007/BF00853590

[CrossRef Full Text](#) | [Google Scholar](#)

50. Tejani A, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. *Kidney Int* (1988) 33(3): 729–34. doi: 10. 1038/ki. 1988. 59

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

51. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a *Streptomyces*. I. Fermentation, isolation, and physico-chemical and biological characteristics. *J Antibiot (Tokyo)* (1987) 40(9): 1249–55. doi: 10. 7164/antibiotics. 40. 1256

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

52. Segarra A, Vila J, Pou L, Majó J, Arbós A, Quiles T, et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. *Nephrol Dial Transplant* (2002) 17(4): 655–62. doi: 10. 1093/ndt/17. 4. 655

[CrossRef Full Text](#) | [Google Scholar](#)

53. Schweda F, Liebl R, Riegger GA, Krämer BK. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. *Nephrol Dial Transplant* (1997) 12(11): 2433–5. doi: 10. 1093/ndt/12. 11. 2433

[CrossRef Full Text](#) | [Google Scholar](#)

54. McCauley J, Tzakis AG, Fung JJ, Todo S, Starzl TE. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. *Lancet* (1990) 335(8690): 674. doi: 10. 1016/0140-6736(90)90471-G

[CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

55. Pennesi M, Gagliardo A, Minisini S. Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome. *Pediatr Nephrol* (2003) 18(5): 477–8. doi: 10. 1007/s00467-003-1098-0

[CrossRef Full Text](#) | [Google Scholar](#)

56. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. *Pediatr Nephrol* (2004) 19(3): 281–7. doi: 10. 1007/s00467-003-1370-3

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

57. Sinha MD, MacLeod R, Rigby E, Clark AGB. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. *Nephrol Dial Transplant* (2006) 21(7): 1848–54. doi: 10. 1093/ndt/gfi274

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

58. Srivastava RN. 50 years of nephrotic syndrome in children, and hereafter. *Indian Pediatr* (2013) 50(1): 107–10. doi: 10. 1007/s13312-013-0024-1

[CrossRef Full Text](#) | [Google Scholar](#)

59. Chandra M, Susin M, Abitbol C. Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. *Pediatr Nephrol* (2000) 14(3): 224–6. doi: 10. 1007/s004670050047

[CrossRef Full Text](#) | [Google Scholar](#)

60. Briggs WA, Choi MJ, Scheel PJ. Successful mycophenolate mofetil treatment of glomerular disease. *Am J Kidney Dis* (1998) 31(2): 213–7. doi: 10.1053/ajkd.1998.v31.pm9469489

[CrossRef Full Text](#) | [Google Scholar](#)

61. Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. *Pediatr Nephrol* (2007) 22(12): 2059–65. doi: 10.1007/s00467-007-0617-9

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

62. Dorresteyn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WCJ, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. *Pediatr Nephrol* (2008) 23(11): 2013–20. doi: 10.1007/s00467-008-0899-6

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

63. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for glomerulonephritis. *Kidney Int Suppl* (2012) 2(2): 139–274. doi: 10.1038/kisup.2012.23

[CrossRef Full Text](#) | [Google Scholar](#)

64. Smith GC. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? *Pediatr Nephrol* (2007) 22(6): 893–8. doi: 10.1007/s00467-006-0427-5

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

65. Benz K, Dötsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. *Pediatr Nephrol* (2004) 19(7): 794–7. doi: 10. 1007/s00467-004-1434-z

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

66. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. *Pediatr Nephrol* (2005) 20(11): 1660–3. doi: 10. 1007/s00467-005-2013-7

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

67. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. *N Engl J Med* (2006) 354(18): 1961–3. doi: 10. 1056/NEJMc055495

[CrossRef Full Text](#) | [Google Scholar](#)

68. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet* (2014) 384(9950): 1273–81. doi: 10. 1016/S0140-6736(14)60541-9

[CrossRef Full Text](#) | [Google Scholar](#)

69. Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, et al. Rituximab for refractory focal segmental glomerulosclerosis. *Pediatr Nephrol* (2008) 23(3): 481–5. doi: 10. 1007/s00467-007-0640-x

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

70. Segarra-Medrano A, Jatem-Escalante E, Agraz-Pamplona I, Carnicer-Cáceres C, Ramos-Terrades N, Ostos-Roldán E, et al. Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors. *Nefrologia* (2013) 33(4): 448–61. doi: 10. 3265/Nefrologia. pre2013. Jan. 11871

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

71. Bayrakci US, Baskin E, Sakalli H, Karakayali H, Haberal M. Rituximab for post-transplant recurrences of FSGS. *Pediatr Transplant* (2009) 13(2): 240–3. doi: 10. 1111/j. 1399-3046. 2008. 00967. x

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

72. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. *Sci Transl Med* (2011) 3(85): 85ra46. doi: 10. 1126/scitranslmed. 3002231

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

73. Bomback AS, Radhakrishnan J. Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH). *Discov Med* (2011) 12(63): 91–6.

[Google Scholar](#)

74. Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H. P. Acthar[®] Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. *Nephrol Dial Transplant* (2014) 29(8): 1570–7. doi: 10. 1093/ndt/gfu069

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

75. Rauen T, Michaelis A, Floege J, Mertens PR. Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. *Clin Nephrol* (2009) 71(6): 637–42. doi: 10. 5414/CNP71637

[CrossRef Full Text](#) | [Google Scholar](#)

76. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotrophic hormone in idiopathic membranous nephropathy. *Am J Kidney Dis* (2006) 47(2): 233–40. doi: 10. 1053/j. ajkd. 2005. 10. 016

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

77. Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, et al. Treatment of idiopathic FSGS with adrenocorticotrophic hormone gel. *Clin J Am Soc Nephrol* (2013) 8(12): 2072–81. doi: 10. 2215/CJN. 02840313

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

78. Berg A-L, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. *Nephrol Dial Transplant* (2004) 19(5): 1305–7. doi: 10. 1093/ndt/gfh110

[CrossRef Full Text](#) | [Google Scholar](#)

79. Gibson KL, Glenn D, Ferris ME. Back to the future: therapies for idiopathic nephrotic syndrome. *Blood Purif* (2015) 39(1–3): 105–9. doi: 10. 1159/000368951

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

80. Greka A. Human genetics of nephrotic syndrome and the quest for precision medicine. *Curr Opin Nephrol Hypertens* (2016) 25(2): 138–43. doi: 10. 1097/MNH. 0000000000000204

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

81. Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, et al. Evolution of the primate trypanolytic factor APOL1. *Proc Natl Acad Sci U S A* (2014) 111(20): E2130–9. doi: 10. 1073/pnas. 1400699111

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

82. Ma L, Shelness GS, Snipes JA, Murea M, Antinozzi PA, Cheng D, et al. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. *J Am Soc Nephrol* (2015) 26(2): 339–48. doi: 10. 1681/ASN. 2013091017

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/history-of-nephrotic-syndrome-and-evolution-of-its-treatment/>

83. Ruchi R, Genovese G, Lee J, Charoonratana VT, Bernhardt AJ, Alper SL, et al. Copy number variation at the APOL1 locus. *PLoS One* (2015) 10(5): e0125410. doi: 10.1371/journal.pone.0125410

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)